Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8689464 | 0.90 | LMNA (0.49) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL24974708 | 0.90 | LMNA (0.49) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL17033159 | 0.87 | EPHX2 (0.47) | EPHX2SPHK1CES2CES1TP53 | |
| SCHEMBL828036 | 0.81 | — | — | |
| SCHEMBL30817551 | 0.81 | MAPT (0.54) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL12040312 | 0.80 | PHF8 (0.50) | HDAC3HDAC1HDAC2HDAC8LMNA | |
| SCHEMBL13146756 | 0.79 | EPHX2 (0.45) | LMNAEPHX2SPHK1CES2CES1 | |
| SCHEMBL23519766 | 0.79 | HDAC1 (0.40) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL16907817 | 0.74 | — | — | |
| SCHEMBL22858686 | 0.74 | HDAC3 (0.43) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377753-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-13 | — | — | US | disclosed |
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-26 | — | — | US | disclosed |
| US-9758537-B2 | Compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208595-A1 | SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS | GRIN2B, GRIN2A, GRIN2C | HDAC3 293/4885HDAC1 198/4885HDAC2 174/4885 |
| US-10377753-B2 | Substituted 4-azaindoles and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | HDAC3 293/4885HDAC1 198/4885HDAC2 174/4885 |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, CFH | HDAC3 2547/4885HDAC1 942/4885HDAC2 1757/4885 |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | HDAC3 4300/4885HDAC1 2715/4885HDAC2 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.